Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aysha Arshad

Clinical Cardiac Electrophysiology Manassas, VA Medical Doctor

NPI 1710964960 CMS profile 78286

8100 Ashton Ave Ste 200, Ste 200, Manassas, VA 20109

Open in the dashboard

General payments

$42,554

429 records reported · program years 2019–2025

Research payments

$13,650

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$40,397 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Aysha Arshad of Manassas, VA is reported in the CMS Open Payments database as having received $42,554 across 429 general payments and $13,650 in research payments paid to them. Separately, studies naming them as principal investigator received $40,397 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,349 125
2024 General $3,223 64
2024 Research $3,150 2
2023 General $3,793 62
2023 Research $10,500 2
2022 General $8,762 63
2021 General $1,615 21
2020 General $8,384 27
2019 General $6,428 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aysha Arshad
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Aysha Arshad were reported at $10,349. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Aysha Arshad Clinical Cardiac Electrophysiology median Middle half National median
2019 $6,428 $2,361 $585–$8,260 $163
2020 $8,384 $993 $247–$4,351 $114
2021 $1,615 $1,185 $326–$4,739 $132
2022 $8,762 $2,073 $554–$6,789 $149
2023 $3,793 $2,568 $759–$8,159 $160
2024 $3,223 $2,557 $703–$7,403 $164
2025 $10,349 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $18,582 127 payments
  2. Medtronic, Inc. $8,157 78 payments
  3. Medtronic Vascular, Inc. $4,771 41 payments
  4. CVRx, Inc. $3,524 11 payments
  5. Boston Scientific Corporation $1,056 21 payments
  6. E.R. Squibb & Sons, L.L.C. $719 24 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $531 14 payments
  8. Novo Nordisk Inc $512 6 payments
  9. Philips Electronics North America Corporation $429 8 payments
  10. Pfizer Inc. $411 16 payments
  11. Other $3,863 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,388 357 payments
  2. Consulting Fee $12,401 9 payments
  3. Travel and Lodging $12,316 62 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $450 1 payment
Products named General payments · program years 2019–2025
  1. Confirm Rx $8,203 18 payments
  2. Barostim Neo System $3,524 11 payments
  3. MICRA $2,505 17 payments
  4. AVEIR Cardiac Rhythm Management $2,237 13 payments
  5. ENSITE PRECISION $1,962 16 payments
  6. NAVITOR $1,494 11 payments
  7. AVEIR Structural Heart $793 10 payments
  8. NA $701 6 payments
  9. Reveal LINQ $646 7 payments
  10. AURORA EV-ICD MRI SURESCAN $635 3 payments
  11. Other $13,344 295 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $13,650 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,667

Median for Cardiology: 2,533

Drug cost

$1,097,664

Median for Cardiology: $485,213

Branded share of claims

36.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 486 $568,479
Xarelto Rivaroxaban Brand 145 $191,744
Entresto Sacubitril/Valsartan Brand 113 $141,870
Jardiance Empagliflozin Brand 50 $66,366
Dofetilide Generic 159 $40,577
Multaq Dronedarone Hcl Brand 14 $30,987
Farxiga Dapagliflozin Propanediol Brand 24 $30,609
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 14 $4,791
Amiodarone Hcl Generic 115 $4,181
Flecainide Acetate Generic 89 $2,732

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$747,163

Medicare's payments for the services billed

Medicare patients

1,690

Average age 78

Services billed

8,952

786 women, 904 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 68%
Ischemic heart disease 49%
Arthritis 49%
Heart failure 40%
Diabetes 36%
Chronic kidney disease 31%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $142
$142 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $122
$122 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $88
  • PFIZER INC. $21
$109 486 —
VYNDAQEL
  • PFIZER INC. $95
$95 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $33
$33 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

433 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record